Cancers in Australia in 2010 attributable to and prevented by the use of menopausal hormone therapy

Australian and New Zealand Journal of Public Health

Volumn 39, Issue 5, 2015, Pages 434-440

  Jordan, Susan J ^a,b   Wilson, Louise F ^a   Nagle, Christina M ^a,b   Green, Adele C ^a,b,c   Olsen, Catherine M ^a,b   Bain, Christopher J ^a,d   Pandeya, Nirmala ^a,b   Whiteman, David C ^a,b   Webb, Penelope M ^a,b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d The Australian National University   (Australia)

Author keywords

cancer; menopausal hormone therapy; population attributable fraction; potential impact fraction; risk factor

Indexed keywords

ADULT; ADVERSE EFFECTS; AUSTRALIA; BREAST NEOPLASMS; CHEMICALLY INDUCED; COLORECTAL TUMOR; ENDOMETRIAL NEOPLASMS; ESTROGEN THERAPY; FEMALE; HUMAN; INCIDENCE; MENOPAUSE; MIDDLE AGED; OVARIAN NEOPLASMS; PREVALENCE; RISK ASSESSMENT; RISK FACTOR;

ADULT; AUSTRALIA; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INCIDENCE; MENOPAUSE; MIDDLE AGED; OVARIAN NEOPLASMS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 84943147462     PISSN: 13260200     EISSN: 17536405     Source Type: Journal    
DOI: 10.1111/1753-6405.12451     Document Type: Article

References (34)

1. Australasian Menopause Society. Australasian Menopause Society New Directions in Womens Health Information Sheet: Glossary of Terms [Internet]. Melbourne (AUST): AMS; 2009 [cited 2014 Apr 6]. Available from: http://www.menopause.org.au/images/stories/infosheets/docs/glossary-of-terms-1.pdf
2. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. C-Gyn 16 Hormone Replacement Therapy Advice [Internet]. Melbourne (AUST): RANZCOG; 2012 [cited 2014 Apr 6]. Available from: http://www.ranzcog.edu.au/doc/hormone-replacement-therapy-advice.html
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288 (3): 321-33.
4. Canfell K, Banks E, Moa AM, Beral V,. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust. 2008; 188 (11): 641-4.
5. Australian Bureau of Statistics. 2004-2005 National Health Survey Expanded CURF, RADL. Findings Based on Use of ABS CURF Data. Canberra (AUST): ABS; 2005.
6. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Hormonal Contraception and Post-menopausal Hormonal Therapy. Volume 72. Lyon (FRC): World Health Organisation; 1999.
7. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Pharmaceuticals. Volume 100 A. A Review of Human Carcinogens. Lyon (FRC): World Health Organisation; 2012.
8. Whiteman DC, Webb PM, Green AC, Neale RE, Fritschi L, Bain CJ, et al., Cancers in Australia in 2010 attributable to modifiable factors: introduction and overview. Aust NZ J Public Health. 2015; 39: 403-7.
9. Collaborative Group On Epidemiological Studies Of Ovarian C. Menopausal hormone use and ovarian cancer risk: Individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015; 385: 1835-42.
10. Australian Bureau of Statistics. 4363.0.55.001-2004-05 National Health Survey: User's Guide-Electronic Publication. Canberra (AUST): ABS; 2006.
11. Fitzgerald D,. Women's Health Australia. The Australian Longitudinal Study on Women's Health. Data Book for the 2010 Phase 6 Survey of the 1945-51 Cohort (aged 59-64 years). Herston (AUST): University of Queensland School of Public Health; 2011 [cited 2013 Mar 4]. Available from: http://www.alswh.org.au/for-researchers/data/data-books
12. Soini T, Hurskainen R, Grenman S, Maenpaa J, Paavonen J, Pukkala E,. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol. 2014; 124 (2 Pt 1): 292-9.
13. Department of Health and Ageing. Australian Statistics on Medicine 2010. Canberra (AUST): Commonwealth of Australia; 2012.
14. Merritt MA, Green AC, Nagle CM, Webb PM, Australian Cancer S, Australian Ovarian Cancer Study G. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer. 2008; 122 (1): 170-6.
15. Australian Institute of Health and Welfare. Cancer Data. Pivot Table [Internet]. Canberra (AUST): AIHW; 2015 [cited 2014 Jun 23]. Available from: http://www.aihw.gov.au/cancer-data/
16. Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, et al., Menopausal hormone therapy and breast cancer risk: Impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2011; 128 (1): 144-56.
17. Beral V, Million Women Study C. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362 (9382): 419-27.
18. Brinton LA, Richesson D, Leitzmann MF, Gierach GL, Schatzkin A, Mouw T, et al., Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev. 2008; 17 (11): 3150-60.
19. Hildebrand JS, Gapstur SM, Feigelson HS, Teras LR, Thun MJ, Patel AV,. Postmenopausal hormone use and incident ovarian cancer: Associations differ by regimen. Int J Cancer. 2010; 127 (12): 2928-35.
20. Pearce CL, Chung K, Pike MC, Wu AH,. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer. 2009; 115 (3): 531-9.
21. Saxena T, Lee E, Henderson KD, Clarke CA, West D, Marshall SF, et al., Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol Biomarkers Prev. 2010; 19 (9): 2366-78.
22. Lin KJ, Cheung WY, Lai JY, Giovannucci EL,. The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer. 2012; 130 (2): 419-30.
23. Parkin DM,. Cancers attributable to exposure to hormones in the UK in 2010. Br J Cancer. 2011; 105 Suppl 2: 42-8.
24. Beral V, Bull D, Reeves G, Million Women Study C. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005; 365 (9470): 1543-51.
25. Morgenstern H, Bursic ES,. A method for using epidemiologic data to estimate the potential impact of an intervention on the health status of a target population. J Community Health. 1982; 7 (4): 292-309.
26. International Agency for Research on Cancer Working Group. Attributable Causes of Cancer in France in the Year 2000. IARC Working Group Reports 3. Lyon (FRC): World Health Organization; 2007.
27. Pike MC, Spicer DV,. Hormonal contraception and chemoprevention of female cancers. Endocr Relat Cancer 2000; 7 (2): 73-83.
28. Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, et al., Hormonal Endocr Relat Cancer contraception and risk of cancer. Hum Reprod Update. 2010; 16 (6): 631-50.
29. Yang HP, Trabert B, Murphy MA, Sherman ME, Sampson JN, Brinton LA, et al., Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study. Int J Cancer. 2012; 131 (4): 938-48.
30. Beral V, Million Women Study C, Bull D, Green J, Reeves G,. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007; 369 (9574): 1703-10.
31. Jansen RP,. Endocrine response in the fallopian tube. Endocr Rev. 1984; 5 (4): 525-51.
32. Barnes EL, Long MD,. Colorectal cancer in women: Hormone replacement therapy and chemoprevention. Climacteric. 2012; 15 (3): 250-5.
33. Karageorgi S, Hankinson SE, Kraft P, De Vivo I,. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004. Int J Cancer. 2010; 126 (1): 208-16.
34. Razavi P, Pike MC, Horn-Ross PL, Templeman C, Bernstein L, Ursin G,. Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2010; 19 (2): 475-83.